Argentum Pharmaceuticals Succeeds in Starting Patent Cancellation Trial Against Mylan’s DYMISTA®

32
0
SHARE

About Argentum Pharmaceuticals
Argentum is a generic drug company with core competencies in intellectual property and pharmaceutical operations. By working with branded and generic pharmaceutical companies and healthcare payors, Argentum intends to reduce the overall cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices.  www.argentumpharmaceuticals.com

About KVK Tech
KVK is a recognized leader in the development and manufacture of high-quality, FDA-approved medicines, and possesses operational expertise in pharmaceutical manufacturing, packaging, sales, distribution, research & development, and customer service. KVK’s expertise runs the gamut and includes solid oral, powder, liquid, and proprietary dosage technologies.  KVK is in the process of expanding its capabilities into aseptic products as well with a 225,000 sq./ft. sterile injectable facility being qualified this year.  KVK takes pride in its ability to advance medical care and offer low-cost, high-quality alternatives in response to today’s healthcare challenges.  KVK is one of the few manufacturers of generic pharmaceuticals which does all its manufacturing, packaging, and distribution in the United States. www.kvktech.com

View original content with multimedia:http://www.prnewswire.com/news-releases/argentum-pharmaceuticals-succeeds-in-starting-patent-cancellation-trial-against-mylans-dymista-300528443.html

SOURCE Argentum Pharmaceuticals

Related Links

http://www.argentumpharmaceuticals.com

Powered by WPeMatico